The FDA has received reports that the use of Mavyret, Zepatier or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver disease has resulted in rare cases of liver injury or liver failure, according to a drug safety communication.
from Google Alert - health https://ift.tt/343Tq1I
via IFTTT
0 comments:
Post a Comment